Patients 18 years or older with R/R DLBCL who received at least 2 prior lines of therapy (de novo DLBCL or from transformed FL, and high‐grade B‐cell lymphoma with MYC rearrangement plus rearrangement of Bcl2, Bcl6 or both). The gene discussed is BCL2; the disease is B-cell non-Hodgkin lymphoma.